BIO-TECHNE Corp
TECHAPI behind this page
TECH Q2 2026 request
Playground key active
/api/financials?ticker=TECH&year=2026&quarter=2
Pick an endpoint and run the request.Income Statement
| Metric | Q2 2026 | Q2 2025 | YoY |
|---|---|---|---|
| Revenue | 295,877 | 297,031 | -0.4% |
Show Product Lines breakouts |
|||
| Consumables | 235,443 | 230,715 | +2.0% |
| Instruments | 29,605 | 30,868 | -4.1% |
| Product and Services | 287,364 | 288,933 | -0.5% |
| Royalty | 8,513 | 8,098 | +5.1% |
| Service | 22,316 | 27,350 | -18.4% |
Show Business Segments breakouts |
|||
| Diagnostics and Spatial Biology · Operating Segments | 81,180 | 84,135 | -3.5% |
| Protein Sciences · Operating Segments | 215,084 | 211,551 | +1.7% |
Show Geography breakouts |
|||
| APAC, excluding Greater China | 22,742 | 19,010 | +19.6% |
| CN | 26,351 | 24,754 | +6.5% |
| EMEA, excluding United Kingdom | 75,354 | 70,392 | +7.0% |
| GB | 13,728 | 13,243 | +3.7% |
| Rest of World | 11,145 | 9,726 | +14.6% |
| US | 146,557 | 159,906 | -8.3% |
Show Consolidation Items breakouts |
|||
| Intersegment Elimination | -387 | -504 | +23.2% |
| Operating Segments | 296,264 | 295,686 | +0.2% |
| Cost of Revenue | 104,600 | 103,145 | +1.4% |
Show Business Segments breakouts |
|||
| Diagnostics and Spatial Biology · Operating Segments | 36,471 | 35,595 | +2.5% |
| Protein Sciences · Operating Segments | 57,030 | 51,927 | +9.8% |
| Gross Profit | 191,277 | 193,886 | -1.3% |
| Selling, General & Administrative | 113,691 | 121,451 | -6.4% |
Show Business Segments breakouts |
|||
| Diagnostics and Spatial Biology · Operating Segments | 27,597 | 35,064 | -21.3% |
| Protein Sciences · Operating Segments | 58,993 | 57,483 | +2.6% |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | -1,037 | -1,641 | +36.8% |
| Research And Development Expense Excluding Acquired In Process Cost | 23,125 | 25,016 | -7.6% |
Show Business Segments breakouts |
|||
| Diagnostics and Spatial Biology · Operating Segments | 8,680 | 10,236 | -15.2% |
| Protein Sciences · Operating Segments | 14,446 | 15,029 | -3.9% |
| Operating Expenses | 136,816 | 146,467 | -6.6% |
| Operating Income | 54,461 | 47,419 | +14.9% |
Show Business Segments breakouts |
|||
| Diagnostics and Spatial Biology · Operating Segments | 8,432 | 3,240 | +160.2% |
| Protein Sciences · Operating Segments | 84,615 | 87,112 | -2.9% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 93,047 | 90,352 | +3.0% |
| Non-Operating Income (Expense) | -3,677 | -4,543 | +19.1% |
| Income Before Taxes | 50,784 | 42,876 | +18.4% |
| Income Tax Expense (Benefit) | 12,775 | 7,986 | +60.0% |
| Net Income | 38,009 | 34,890 | +8.9% |
| Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent | 2,762 | -25,518 | +110.8% |
| Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax Parent | -711 | -45 | -1480.0% |
| Other Comprehensive Income Loss Net Of Tax | 2,051 | -25,563 | +108.0% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | 2,051 | -25,563 | +108.0% |
| Comprehensive Income | 40,060 | 9,327 | +329.5% |
| EPS (Basic) | 0.24 | 0.22 | +9.1% |
| EPS (Diluted) | 0.24 | 0.22 | +9.1% |
| Wtd Avg Shares (Basic) | 155,839 | 158,431 | -1.6% |
| Wtd Avg Shares (Diluted) | 156,999 | 160,626 | -2.3% |
| Revenue | 295,877 | 297,031 | -0.4% |
| Interest Expense | -2,171 | -2,148 | -1.1% |
| Other Comprehensive Income (Q) | — | — | — |
Show Equity Components breakouts |
|||
| Accumulated Net Unrealized Investment Gain Loss | -711 | -45 | -1480.0% |
| Accumulated Other Comprehensive Income | 2,051 | -25,563 | +108.0% |
| Accumulated Translation Adjustment | 2,762 | -25,518 | +110.8% |
| Net Income Loss Available To Common Stockholders Basic | 38,003 | 34,887 | +8.9% |
| Income Loss From Equity Method Investments | 110 | 46 | +139.1% |
Balance Sheet
| Metric | Q2 2026 | Q2 2025 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 172,879 | 177,549 | -2.6% |
| Accounts Receivable | 184,614 | 217,940 | -15.3% |
| Inventory | 205,447 | 188,373 | +9.1% |
| Other Assets Current | 74,492 | 49,731 | +49.8% |
| Total Current Assets | 637,432 | 634,640 | +0.4% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 234,383 | 249,753 | -6.2% |
| Operating Lease Right-of-Use Assets | 68,249 | — | — |
| Goodwill | 980,561 | — | — |
Show Business Segments breakouts |
|||
| Diagnostics and Spatial Biology | 554,670 | — | — |
| Protein Sciences | 425,891 | — | — |
| Other Non-Current Assets | 267,084 | 274,990 | -2.9% |
| Total Assets | 2,522,699 | 2,670,424 | -5.5% |
| Intangible Assets | 334,990 | — | — |
| Long Term Investments (Q) | — | — | — |
Show Schedule Of Equity Method Investment Equity Method Investee Name breakouts |
|||
| Spear Bio · Other Noncurrent Assets | 15 | 15 | 0.0% |
| Other Assets | |||
| Intangible Assets Net Excluding Goodwill | 334,990 | — | — |
| Current Liabilities | |||
| Accounts Payable | 26,269 | 33,120 | -20.7% |
| Employee Related Liabilities Current | 45,026 | 53,594 | -16.0% |
| Accrued Liabilities | 20,337 | 27,543 | -26.2% |
| Deferred Revenue (Current) | 31,030 | 27,715 | +12.0% |
| Accrued Income Taxes Current | 2,476 | 3,141 | -21.2% |
| Operating Lease Liability Current | 13,710 | — | — |
| Other Liabilities Current | 1,578 | 2,632 | -40.0% |
| Total Current Liabilities | 140,426 | 161,256 | -12.9% |
| Non-Current Liabilities | |||
| Deferred Tax Liabilities | 11,021 | — | — |
| Operating Lease Liabilities | 77,185 | — | — |
| Other Non-Current Liabilities | 23,078 | 11,337 | +103.6% |
| Other Liabilities | |||
| Long Term Debt And Capital Lease Obligations | 260,000 | 300,000 | -13.3% |
| Stockholders' Equity | |||
| Common Stock | 1,559 | 1,579 | -1.3% |
| Additional Paid In Capital Common Stock | 964,955 | 875,864 | +10.2% |
| Retained Earnings | 1,106,819 | 1,286,699 | -14.0% |
| Accumulated Other Comprehensive Income | -62,344 | -85,650 | +27.2% |
| Total Stockholders' Equity | 2,010,989 | — | — |
Show Equity Components breakouts |
|||
| Accumulated Net Unrealized Investment Gain Loss | 160 | 5,030 | -96.8% |
| Accumulated Other Comprehensive Income | -62,344 | -85,650 | +27.2% |
| Accumulated Translation Adjustment | -62,504 | -90,680 | +31.1% |
| Total Liabilities & Equity | 2,522,699 | 2,670,424 | -5.5% |
Cash Flow Statement
| Metric | YTD Q2 2026 | YTD Q2 2025 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Net Income (Q) | — | — | — |
Show Equity Components breakouts |
|||
| Retained Earnings | 38,009 | 34,890 | +8.9% |
| Net Income | 76,194 | 68,490 | +11.2% |
| Depreciation & Amortization | 49,049 | 55,221 | -11.2% |
| Deferred Income Taxes And Tax Credits | 5,203 | -13,417 | +138.8% |
| Stock-Based Compensation | 25,640 | 24,892 | +3.0% |
| Equity Method Investment Realized Gain Loss On Disposal | -404 | -420 | +3.8% |
| Unrealized Gain Loss On Investments | -37 | — | — |
| Asset Impairment Restructuring Charge | 3,253 | 9,841 | -66.9% |
| Noncash Portion Of Lease Expense | -1,780 | 492 | -461.8% |
| Recovery Of Assets Held For Sale | -6,789 | — | — |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | -6,789 | — | — |
| Other Operating Activities Cash Flow Statement | 663 | 305 | +117.4% |
| Increase Decrease In Accounts And Other Receivables | 23,333 | 20,940 | +11.4% |
| Change in Inventory | -15,941 | -11,713 | -36.1% |
| Increase Decrease In Prepaid Expense | 3,255 | -405 | +903.7% |
| Increase Decrease In Accounts Payable And Accrued Liabilities | -8,107 | -29 | -27855.2% |
| Increase Decrease In Employee Related Liabilities | -20,708 | 3,882 | -633.4% |
| Increase Decrease In Accrued Income Taxes Payable | -22,828 | -10,217 | -123.4% |
| Net Cash from Operations | 109,996 | 148,235 | -25.8% |
| Investing Activities | |||
| Capital Expenditures | -11,284 | -15,993 | +29.4% |
| Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital | 1,351 | 1,403 | -3.7% |
| Proceeds From Sale Of Property Held For Sale | 4,617 | 1,789 | +158.1% |
| Net Cash from Investing | -5,316 | -26,716 | +80.1% |
| Financing Activities | |||
| Payments Of Dividends Common Stock | -24,914 | -25,424 | +2.0% |
| Proceeds From Stock Options Exercised | 28,234 | 30,641 | -7.9% |
| Share Repurchases | -24 | -75,628 | +100.0% |
| Repayments Of Lines Of Credit | -86,000 | -19,000 | -352.6% |
| Tax Withholding for Share Compensation | -10,486 | -5,997 | -74.9% |
| Net Cash from Financing | -93,190 | -95,408 | +2.3% |
| Supplemental | |||
| Income Taxes Paid | 36,683 | 37,593 | -2.4% |
| Interest Paid | 8,809 | 9,831 | -10.4% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | -797 | -353 | -125.8% |
| Net Change in Cash | 10,693 | 25,758 | -58.5% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 172,879 | 177,549 | -2.6% |
Values in thousands USD. Source: SEC EDGAR 10-Q filing.